Cephalexin
Genetic Predisposition to Disease
University of California, San FranciscoSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Genetic Predisposition to Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aln-Pnp Regeneron Pharmaceuticals | Phase 1 | CC |
Minoxidil Duke University | Phase 1 | CC |
Fluconazole Bochud Pierre-Yves | N/A | D |
Posaconazole Bochud Pierre-Yves | N/A | D |
BLOOD, WHOLE University Hospital, Lille | D |
Same molecule, other indications
Cephalexin is also rated in:
methicillin-susceptible staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
65 / 100
View asset →methicillin-resistant staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →